Cytotoxic T-lymphocyte differentiation and cytogenetic alterations in gammadelta hepatosplenic T-cell lymphoma and posttransplant lymphoproliferative disorders.
Salhany
K E
KE
Feldman
M
M
Peritt
D
D
Nowell
P C
PC
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002897:Chromosomes, Human, Pair 7; D003520:Cyclophosphamide; D004317:Doxorubicin; D006801:Humans; D016030:Kidney Transplantation; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D011183:Postoperative Complications; D011239:Prednisolone; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000235:genetics*; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000473:pathology; D014314:Trisomy; D014750:Vincristine
D016693:Receptors, Antigen, T-Cell, alpha-beta; D016692:Receptors, Antigen, T-Cell, gamma-delta; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone